B4GALT1 and colorectal carcinoma: By means of dd-QMSP we analyzed hypermethylated B4GALT1 in plasma specimens of two independent sample cohorts of mCRC cases (Group 3 and 4), showing that the assessment of B4GALT1 methylation is able to clearly discriminate CRC patients from healthy control subjects (ROC analysis: AUC = 0.750; 95% CI: 0.592–0.908, p = 0.008), with a 100% specificity and a 50% sensitivity.